These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25561461)

  • 1. Phosphatidylinositol inhibits respiratory syncytial virus infection.
    Numata M; Kandasamy P; Nagashima Y; Fickes R; Murphy RC; Voelker DR
    J Lipid Res; 2015 Mar; 56(3):578-587. PubMed ID: 25561461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
    Numata M; Chu HW; Dakhama A; Voelker DR
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):320-5. PubMed ID: 20080799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innate and adaptive cellular phenotypes contributing to pulmonary disease in mice after respiratory syncytial virus immunization and infection.
    Lee YT; Kim KH; Hwang HS; Lee Y; Kwon YM; Ko EJ; Jung YJ; Lee YN; Kim MC; Kang SM
    Virology; 2015 Nov; 485():36-46. PubMed ID: 26196232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylglycerol provides short-term prophylaxis against respiratory syncytial virus infection.
    Numata M; Nagashima Y; Moore ML; Berry KZ; Chan M; Kandasamy P; Peebles RS; Murphy RC; Voelker DR
    J Lipid Res; 2013 Aug; 54(8):2133-2143. PubMed ID: 23749985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional disorder of primary immunity responding to respiratory syncytial virus infection in offspring mice exposed to a flame retardant, decabrominated diphenyl ether, perinatally.
    Watanabe W; Shimizu T; Sawamura R; Hino A; Konno K; Kurokawa M
    J Med Virol; 2010 May; 82(6):1075-82. PubMed ID: 20419825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung.
    Numata M; Grinkova YV; Mitchell JR; Chu HW; Sligar SG; Voelker DR
    Int J Nanomedicine; 2013; 8():1417-27. PubMed ID: 23717040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses.
    Olivier AK; Gallup JM; van Geelen A; Ackermann MR
    Exp Lung Res; 2011 Apr; 37(3):131-43. PubMed ID: 21309731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans.
    Sun Y; Jain D; Koziol-White CJ; Genoyer E; Gilbert M; Tapia K; Panettieri RA; Hodinka RL; López CB
    PLoS Pathog; 2015 Sep; 11(9):e1005122. PubMed ID: 26336095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by modulating macrophage phagocytic capacity.
    Wronski S; Dannenmaier J; Schild S; Macke O; Müller L; Burmeister Y; Seilheimer B; Müller M
    PLoS One; 2018; 13(4):e0195822. PubMed ID: 29672626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus prevents the subsequent development of ovalbumin-induced allergic responses by inhibiting ILC2 via the IL-33/ST2 pathway.
    Wang D; Bai S; Cui Y; Zhao N; Qi F; Liu J; Zeng S; Xu L; Hu H; Liu B
    Immunotherapy; 2018 Sep; 10(12):1065-1076. PubMed ID: 30027786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Responses by Human Respiratory Epithelial Cell Lines to Respiratory Syncytial Virus Reflect Distinct Patterns of Infection Control.
    Hillyer P; Shepard R; Uehling M; Krenz M; Sheikh F; Thayer KR; Huang L; Yan L; Panda D; Luongo C; Buchholz UJ; Collins PL; Donnelly RP; Rabin RL
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29769339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.
    Martinez-Sobrido L; Gitiban N; Fernandez-Sesma A; Cros J; Mertz SE; Jewell NA; Hammond S; Flano E; Durbin RK; García-Sastre A; Durbin JE
    J Virol; 2006 Feb; 80(3):1130-9. PubMed ID: 16414990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection.
    Harker JA; Lee DC; Yamaguchi Y; Wang B; Bukreyev A; Collins PL; Tregoning JS; Openshaw PJ
    J Virol; 2010 May; 84(10):5294-302. PubMed ID: 20200251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
    Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
    J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.
    Lee YN; Suk Hwang H; Kim MC; Lee YT; Cho MK; Kwon YM; Seok Lee J; Plemper RK; Kang SM
    Virology; 2015 Feb; 476():217-225. PubMed ID: 25553517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.